2025-10-14 - Analysis Report
Okay, here's the analysis of TG Therapeutics Inc. (TGTX), incorporating the provided data and aiming for a concise, English report with numerical highlights and interpretive summaries:

**Report on TG Therapeutics Inc. (TGTX)**

**0. Executive Summary**

TG Therapeutics Inc. (TGTX) is a biopharmaceutical company focused on the development and commercialization of novel therapies for the treatment of B-cell malignancies and autoimmune diseases.  While TGTX has shown revenue and profit margin, the company has been underperforming the S\&P 500. Recent news highlights positive developments in their multiple sclerosis treatment, BRIUMVI. Analyst sentiment is generally positive.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return:** TGTX: 80.54%, VOO: 96.68%
*   **Disparity:** Current difference of -19.8%.
*   **Relative Disparity:** 20.0 (Indicates TGTX's current performance relative to its historical range compared to VOO).

**Analysis:** TGTX has underperformed the S&P 500 based on cumulative returns. The relative disparity metric suggests its current underperformance is closer to the lower end of its historical range compared to the index.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
|------------|---------|-------|---------|--------|--------|
| 2015-2017  | -5.0%   | 73.5% | -33.0%  | -0.0   | 1.3    |
| 2016-2018  | -12.0%  | 73.5% | -27.0%  | -0.0   | 0.7    |
| 2017-2019  | 74.0%   | 74.1% | 52.0%   | 0.0    | 1.8    |
| 2018-2020  | 316.0%  | 74.1% | 293.0%  | 0.1    | 8.2    |
| 2019-2021  | 124.0%  | 74.1% | 78.0%   | 0.3    | 3.0    |
| 2020-2022  | -71.0%  | 77.8% | -71.0%  | -0.0   | 1.9    |
| 2021-2023  | -284.0% | 77.8% | -285.0% | -1.1   | 2.7    |
| 2022-2024  | 56.0%   | 77.8% | 36.0%   | -1.0   | 4.8    |
| 2023-2025  | 81.0%   | 74.8% | 20.0%   | -0.1   | 5.4    |

**Analysis:**

*   **CAGR:** Fluctuating significantly, with high volatility.
*   **MDD:** High Maximum Drawdown suggests substantial risk.
*   **Alpha:** Periods of significant outperformance (positive alpha) mixed with periods of significant underperformance (negative alpha).
*   **Beta:** Generally low beta values indicate low correlation with the market.

**2. Recent Stock Price Movements**

*   **Current Price:** 34.22
*   **Previous Close:** 33.76
*   **Change:** 1.36
*   **5-day Moving Average:** 34.84
*   **20-day Moving Average:** 34.93
*   **60-day Moving Average:** 32.41

**Analysis:** The current price is above the 60-day moving average but below the 5-day and 20-day averages, suggesting a possible recent upward trend that may be losing momentum. The 1.36 change signifies a recent positive uptick.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 40.10 (Neutral)
*   **PPO:** -1.03 (Negative)
*   **Hybrid Signal:** Buy 100% (Very Safe - MRI:0.90)
*   **Delta_Previous_Relative_Divergence:** -3.6 (Short-term Decrease)
*   **Expected Return (%):** -115.8%

**Analysis:** The MRI suggests a medium investment risk. The RSI is neutral, not indicating overbought or oversold conditions. The negative PPO suggests a downtrend. The hybrid signal is recommending a buy but the the Expected Return is very bad. The recent negative change in relative disparity indicates short-term downward momentum.

**4. Recent News & Significant Events**

*   **Positive BRIUMVI Data:** Multiple news items highlight positive 6-year data for BRIUMVI, showing a high percentage of multiple sclerosis patients free from progression.
*   **Institutional Investor Activity:**  Institutional investors are increasing their positions in TGTX.

**Analysis:** Positive clinical data on BRIUMVI is a significant catalyst for the stock. Increased institutional investment indicates confidence in the company's prospects.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.78)
*   **Target Price:** Average: 43.57, High: 60.00, Low: 11.00

**Analysis:**  Analysts are generally positive on TGTX, with a consensus rating of "Buy."  The wide range in target prices suggests uncertainty about the company's future valuation.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue   |
|------------|------|-----------|
| 2025-08-08 | 0.19 | 0.14 B$   |
| 2025-05-09 | 0.03 | 0.12 B$   |
| 2024-11-07 | 0.03 | 0.08 B$   |
| 2024-08-09 | 0.05 | 0.07 B$   |
| 2025-08-08 | 0.05 | 0.07 B$   |

**Analysis:**  Recent EPS and revenue figures show increasing growth.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.14B  | 86.58%        |
| 2025-03-31 | $0.12B  | 87.14%        |
| 2024-12-31 | $0.11B  | 85.77%        |
| 2024-09-30 | $0.08B  | 88.86%        |
| 2024-06-30 | $0.07B  | 88.70%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE     |
|------------|---------|---------|
| 2025-06-30 | $0.28B  | 10.20%  |
| 2025-03-31 | $0.24B  | 2.13%   |
| 2024-12-31 | $0.22B  | 10.49%  |
| 2024-09-30 | $0.19B  | 2.02%   |
| 2024-06-30 | $0.18B  | 3.87%   |

**Analysis:** Revenue and profit margin are generally increasing, indicating improved financial performance. Equity is growing, and ROE fluctuates, reflecting changes in profitability relative to equity.

**7. Overall Assessment**

TG Therapeutics (TGTX) presents a mixed picture. While it has underperformed the S&P 500 in cumulative returns, recent positive clinical data for BRIUMVI and increasing institutional investment are encouraging signs. Analyst sentiment is generally positive.

**Key Considerations:**

*   **BRIUMVI's Success:** Continued positive data and market adoption of BRIUMVI are crucial for future growth.
*   **Volatility:** TGTX exhibits high volatility and risk, as indicated by MDD.
*   **Financial Performance:** The recent revenue and profit margin trends are positive.
*   **Future Earning:**The Expected Return(%) is a concern.
